Stratasys Ltd (Stratasys) is a provider of 3D printing, related services, and consumables, and additive manufacturing solutions. Stratasys 3D printing applications include manufacturing, jigs and fixtures, production parts, rapid prototyping, packaging, design, composite tooling and dentures. It offers printers such as FDM, PolyJet, Stereolithograph, P3 and SAF.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s Research and Development (R&D) activities focus on the development of new materials and systems, improving its product lines and adding new capabilities to its systems and related materials and software. It focuses on significant technology platform developments for FDM, PolyJet, SAF and SCP technologies, AM systems including integrated software, and family of proprietary acrylic-based photopolymer materials for PolyJet printing and family of proprietary thermoplastic materials for FDM printing. The company also focuses on customer requested enhancements, and development of new modeling processes, software, and user applications. As of December 2023, the company had 2,600 granted and pending patent applications, internationally. Its consumable materials production and development operations are located in Eden Prairie, Minnesota; Rehovot, Israel; Kiryat Gat, Israel; Elgin, Illinois, the US; Geleen, Netherlands; and Lengwil, Switzerland. In FY2023, the company incurred expenses of US$94.4 million in its R&D activities, which as a percentage of revenue, stood at 15%.